AptuScan acquisition will take Avacta to next level of growth, says CEO
This article was originally published in Clinica
Executive Summary
UK analysis and detection technologies specialist Avacta is to go ahead with its proposed acquisition of proprietary reagents developer AptuScan after shareholders yesterday approved the deal and the £5.13m ($7.9m) share placement that will finance the transaction.